AFP and hepatocellular carcinoma: Positivity rate of monomeric Ln-γ2 in patients with HCC for each TMN stage was 50% in stage I, 67% in stage II, 62% in stage III, and 75% in stage IV, respectively, whereas that of AFP was 20% in stage I, 44% in stage II, 67% in stage III, and 75% in stage IV, respectively, and of PIVKA-II was 50% in stage I, 56% in stage II, 76% in stage III, and 88% in stage IV, respectively (Figure 9) [32].